Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Here's my best go at explaining how George Osborne magicked away his tax credits headache.
A baby boy was found abandoned in a church's nativity manger with his umbilical cord still attached.
At least 30 people, mainly patients, were killed when US forces began firing at the facility "mistakenly" thinking it was a Taliban base.